PaceMate Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management

PaceMate, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE: MDT.) This strategic move significantly expands PaceMate’s reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate’s ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management.

“After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs,” said Kweli P. Thompson, M.D., M.P.H., senior vice president and president, Medtronic Cardiac Rhythm Management. “PaceMate offers best-in-class cardiac data management solutions and will provide excellent ongoing support to Paceart customers.”

Medtronic Cardiac Rhythm Management and PaceMate will collaborate closely to ensure a seamless transition and maintain exceptional service for Paceart customers. “Our shared values, dedication to customer experience, and commitment to exceptional patient-centric cardiac solutions make this agreement a perfect fit,” said Tripp Higgins, CEO of PaceMate. “Paceart customers will benefit from the continued support of Paceart employees transitioning to PaceMate, as well as enhanced service delivery and innovation. We are excited to set a new standard in the market by combining the strengths of both technologies for unparalleled support and advancement.”

PaceMate delivers the industry’s leading comprehensive end-to-end platform, supporting the full spectrum of cardiac device types, including implantables, ambulatory monitors, heart failure devices, and remote patient monitors. This is paired with a complete suite of flexible solutions, including software, patient communications, and clinical service support.

PaceMate’s flagship product, PaceMateLIVE™, is recognized as the best-in-class remote cardiac monitoring software, leveraging powerful EHR integrations for seamless implementation, intuitive use, and intelligent patient prioritization. With the leading robust, research-grade data set, healthcare organizations have access to the most advanced tools for optimizing clinic operations and leveraging patient-centric data to conduct ground-breaking research. This acquisition complements PaceMate and brings it to the forefront of global cardiac care, enabling better patient outcomes and global innovation.

SourcePaceMate

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.